mitoxantrone has been researched along with Genetic Predisposition in 6 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We analyzed polymorphic variants of DNA repair and detoxification genes in patients with multiple sclerosis (MS) who developed secondary acute promyelocytic leukemia (sAPL), in most cases after treatment with mitoxantrone (MTZ)." | 3.77 | Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. ( Bernardi, G; Buttari, F; Centonze, D; Cicconi, L; Garagnani, P; Hasan, SK; Hohaus, S; Lo-Coco, F; Mantovani, V; Marasco, E; Ottone, T; Sanz, MA; Voso, MT, 2011) |
| "Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2." | 3.70 | Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. ( Ashley, S; Kuan, A; Kulkarni, S; Mehta, J; Mitchell, P; Powles, R; Powles, T; Saso, R; Swansbury, GJ; Treleaven, J, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boddu, PC | 1 |
| Zeidan, AM | 1 |
| Kümpfel, T | 1 |
| Hoffmann, LA | 1 |
| Pellkofer, H | 1 |
| Pöllmann, W | 1 |
| Feneberg, W | 1 |
| Hohlfeld, R | 1 |
| Lohse, P | 1 |
| Dörr, J | 1 |
| Bitsch, A | 1 |
| Schmailzl, KJ | 1 |
| Chan, A | 1 |
| von Ahsen, N | 1 |
| Hummel, M | 1 |
| Varon, R | 1 |
| Lill, CM | 1 |
| Vogel, HP | 1 |
| Zipp, F | 1 |
| Paul, F | 1 |
| Hasan, SK | 1 |
| Buttari, F | 1 |
| Ottone, T | 1 |
| Voso, MT | 1 |
| Hohaus, S | 1 |
| Marasco, E | 1 |
| Mantovani, V | 1 |
| Garagnani, P | 1 |
| Sanz, MA | 1 |
| Cicconi, L | 1 |
| Bernardi, G | 1 |
| Centonze, D | 1 |
| Lo-Coco, F | 1 |
| Pender, MP | 1 |
| Wolfe, NP | 1 |
| Saso, R | 1 |
| Kulkarni, S | 1 |
| Mitchell, P | 1 |
| Treleaven, J | 1 |
| Swansbury, GJ | 1 |
| Mehta, J | 1 |
| Powles, R | 1 |
| Ashley, S | 1 |
| Kuan, A | 1 |
| Powles, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)[NCT01627938] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mitoxantrone and Genetic Predisposition
| Article | Year |
|---|---|
Myeloid disorders after autoimmune disease.
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Genetic Predisposition to Disease; Humans; Immunosuppressiv | 2019 |
Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
Topics: Adjuvants, Immunologic; Autoimmune Diseases; Azathioprine; B-Lymphocytes; Cyclophosphamide; Disease | 2002 |
4 other studies available for mitoxantrone and Genetic Predisposition
| Article | Year |
|---|---|
Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arginine; Familial Mediterranean F | 2008 |
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tr | 2009 |
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.
Topics: Adult; Antineoplastic Agents; DNA Repair Enzymes; Genetic Predisposition to Disease; Humans; Leukemi | 2011 |
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2000 |